NCT02597166View on ClinicalTrials.gov

Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Hepatitis C, ChronicCirrhosis, Decompensated
Interventions
DRUG

Ledipasvir/Sofosbuvir

Each tablet of Harvoni contains 90 mg ledipasvir and 400 mg sofosbuvir.

Trial Locations (1)

M5G 2C4

University Health Network - Toronto General Hospital, Toronto

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

University Health Network, Toronto

OTHER